PCM
MYGN icon

Prelude Capital Management’s Myriad Genetics MYGN Stock Holding History

Prelude Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,029
Closed -$66K – 1736
2020
Q3 		$66K Buy
5,029
+4,762
+1,784% +$60.3K ﹤0.01% 1050
2020
Q2 		$3K Buy
+267
New +$3.79K ﹤0.01% 1787
2019
Q1 		– Sell
-282
Closed -$8K – 2022
2018
Q4 		$8K Buy
282
+118
+72% +$4.25K ﹤0.01% 1420
2018
Q3 		$8K Sell
164
-253
-61% -$11.3K ﹤0.01% 1535
2018
Q2 		$16K Buy
+417
New +$14.1K ﹤0.01% 1394
2017
Q3 		– Sell
-12,092
Closed -$312K – 1811
2017
Q2 		$312K Sell
12,092
-30,018
-71% -$637K 0.03% 447
2017
Q1 		$809K Buy
42,110
+10,211
+32% +$181K 0.08% 262
2016
Q4 		$532K Buy
31,899
+24,491
+331% +$443K 0.06% 309
2016
Q3 		$152K Buy
7,408
+2,808
+61% +$71.2K 0.02% 655
2016
Q2 		$141K Buy
+4,600
New +$160K 0.02% 618
2015
Q3 		– Sell
-550
Closed -$19K – 1674
2015
Q2 		$19K Sell
550
-550
-50% -$18.7K ﹤0.01% 1389
2015
Q1 		$39K Buy
+1,100
New +$39.4K 0.01% 1454
2014
Q4 		– Sell
-12,521
Closed -$483K – 2068
2014
Q3 		$483K Sell
12,521
-515
-4% -$19.2K 0.07% 380
2014
Q2 		$507K Buy
13,036
+1,921
+17% +$71.5K 0.07% 373
2014
Q1 		$380K Buy
11,115
+1,090
+11% +$33.8K 0.05% 506
2013
Q4 		$210K Buy
10,025
+2,863
+40% +$72.4K 0.03% 608
2013
Q3 		$168K Buy
+7,162
New +$203K 0.03% 586

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's MYGN Position: Q4 2020 in Review

Prelude Capital Management sold out of Myriad Genetics (MYGN) in Q4 2020, closing a stake of 5,029 shares — an estimated $66K sold.

Prelude Capital Management first reported a position in MYGN in Q3 2013 and held it in 17 quarters. The position peaked at $809K in Q1 2017. 187 funds tracked by Wall St. Rank hold MYGN as of Q4 2020.

  • Prelude Capital Management reported no remaining Myriad Genetics position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 5,029 Myriad Genetics shares in Q4 2020, an estimated $66K.
  • Prelude Capital Management first reported a position in Myriad Genetics in Q3 2013 and held it in 17 quarters.
  • Prelude Capital Management's Myriad Genetics position peaked at $809K in Q1 2017.
  • 187 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.